Tocagen Inc

Tocagen — Corporate Update (November 2019)

31 slides from Tocagen's corporate update, Nov 22, 2019

  1. Slide 1: A Cancer-Selective Gene Therapy Company

    A Cancer-Selective Gene Therapy Company Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Tocagen Inc. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify

  3. Slide 3: Tocagen At-A-Glance

    Tocagen At-A-Glance San Diego, California biotechnology company Founded by pioneers of gene therapy Vision: No One Should Die Of Cancer Core technology is a differentiated retroviral replicating vector (RRV) platform Currently exploring strategic alternatives* *Tocagen has retained Ladenburg Thalman

  4. Slide 4: Retroviral Replicating Vector (RRV) Gene Therapy Platform

    Retroviral Replicating Vector (RRV) Gene Therapy Platform Selective Infection, Spread and Persistence in Cancer Cells RRVs Infect Immune Deficient Cancer Cells But Not Normal Cells With Intact Immune Systems Cancer cell interferon pathway genetic defects reduce anti-retroviral resistance Brain tumor

  5. Slide 5: RRV Platform Has the Potential to Deliver a Variety of Therapeutic Genes

    RRV Platform Has the Potential to Deliver a Variety of Therapeutic Genes IL-2 IL-12 IL-15 αPD-L1 Cytosine deaminase (Toca 511) with prodrug (Toca FC) Thymidine kinase Purine nucleoside phosphorylase Anti-PD-L1 OX40L scFv ab Cytokines Enzymes siRNA Immune Agonists GMCSF + cytosine deaminase Gene Comb

  6. Slide 6: Lead Program - Toca 511 & Toca FC: Immune Activation Via the Tumor Microenvironment

    Lead Program - Toca 511 & Toca FC Immune Activation Via the Tumor Microenvironment 5-FU also eliminates immunosuppressive myeloid cells (MDSCs and TAMs), activating antitumor immunity Gamma retrovirus Toca 511 selectively infects tumor, persists and spreads through tumor while delivering the CD gene

  7. Slide 7: Toca 511 & Toca FC Activates a Durable Anti-Cancer Immune Response in Preclinical Models

    Toca 511 & 5-FC Activates a Durable Anti-Cancer Immune Response in Preclinical Models Locally, within tumor microenvironment, Toca 511 & Toca FC alter immune profile Increased T cell immune infiltrates in tumor (COLD → HOT) Immune effects are CD4 & CD8 T cell-dependent and correlate with immune-supp

  8. Slide 8: Toca 511-11-01 Overall Survival and the Best Response

    Toca 511-11-01 Overall Survival and the Best Response 1st/2nd Recurrence, No prior bevacizumab, <=5cm, Higher Dose Cohorts (N=23) Phase 1 Resection Study: Long-Term Survival in Higher Dose Cohort All Responses are Durable Complete Responses & Associated with Long Term Survival AA, IDH1 mt GBM, IDH1

  9. Slide 9: Toca 5 Phase 3 Trial in Recurrent High Grade Glioma

    Toca 5 Phase 3 Trial in Recurrent High Grade Glioma One of the Largest Trials in rHGG with Enrollment of 403 Patients ClinicalTrials.gov Identifier: NCT02414165 * Administered at time of surgery ** Begins 6 weeks post-surgery Surgery And Randomization N=403 Toca 511* Toca FC** Chemotherapy** (lomust

  10. Slide 10: Toca 5 Primary Endpoint - Overall Survival Did Not Meet Statistical Significance

    Toca 5 Primary Endpoint - Overall Survival Did Not Meet Statistical Significance Intention-to-treat (ITT) Nominal significance level for this analysis 0.0232 HR=1.06 (95%CI: 0.83, 1.35) p-value=0.6154 Median OS: Toca: 11.07 months SOC: 12.22 months Intention-To-Treat – Overall Survival

  11. Slide 11: Secondary Endpoints Did Not Meet Statistical Significance

    Secondary Endpoints Did Not Meet Statistical Significance Intention-to-Treat Population Toca 511 and Toca FC arm (N=201) SOC arm (N=202) HR (95% CI) p-value Durable response rate (%) 5 (2.5) 9 (4.5) NA 0.4156 Durable clinical benefit rate (%) 5 (2.5) 9 (4.5) NA 0.4156 Duration of durable response (m

  12. Slide 12: Toca Regimen Favored in Pre-Specified Subgroups - Forest Plot

    Toca Regimen Favored in 2nd Recurrence, AA, and IDH1mt Pre-Specified Subgroups - Forest Plot for Overall Survival Hazard Ratio Favoring Toca Favoring SOC Hazard Ratio (Toca vs. SOC) & 95% C.I. (Log Scale) P-values not adjusted for multiple settings 1 2 3

  13. Slide 13: Overall Survival – IDH1mt Subgroup and AA Subgroup

    Overall Survival – Intention-To-Treat (ITT) IDH1mt Subgroup and AA Subgroup HR=0.64 (95%CI: 0.33, 1.24) p-value=0.1853 Median OS: Toca: 17.64 months SOC: 12.45 months Intention-To-Treat – IDH1mutant Intention-To-Treat – Anaplastic Astrocytoma (AA) HR=0.57 (95%CI: 0.28, 1.14) p-value=0.1057 Median OS

  14. Slide 14: Overall Survival (ITT) - Second Recurrence Subgroup

    Overall Survival (ITT) - Second Recurrence Subgroup Toca 511 & Toca FC Showed ~2X Median Survival over SOC Intention-To-Treat – Second Recurrence HR=0.43 (95%CI: 0.21, 0.87) p-value=0.0162 Median OS: Toca: 21.82 months SOC: 11.14 months Toca 511 and Toca FC (N=28) Standard of Care (N=32) Total (N=60

  15. Slide 15: Second Recurrence Survival By Tumor Histology (post hoc analysis)

    Overall Survival – Second Recurrence Survival By Tumor Histology (post hoc analysis) Glioblastoma Multiforme (GBM) Anaplastic Astrocytoma (AA) HR=0.73 (95%CI: 0.35, 1.53) p-value=0.4051 Median OS: Toca: 13.17 months SOC: 11.17 months HR=NE (95%CI: NE, NE) p-value=0.0007 Median OS: Toca: NR SOC: 9.07

  16. Slide 16: Second Recurrence Survival by IDH1 Mutation Status (post hoc analysis)

    Overall Survival – Second Recurrence Survival by IDH1 Mutation Status (post hoc analysis) HR=0.68 (95% CI: 0.30, 1.52) p-value=0.3456 Median OS: Toca: 14.85 months SOC: 11.17 months HR=0.14 (95% CI: 0.03, 0.69) p-value=0.0063 Median OS: Toca: NR (Not Reached) SOC: 10.87 months NR=Not Reached IDH1 wi

  17. Slide 17: Second Recurrence Survival by MGMT Methylation Status (post hoc analysis)

    Overall Survival – Second Recurrence Survival by MGMT Methylation Status (post hoc analysis) HR=0.35 (95%CI: 0.11, 1.10) p-value=0.0609 Median OS: Toca: 22.47 months SOC: 13.01 months HR=0.57 (95% CI: 0.23, 1.40) p-value=0.2126 Median OS: Toca: 14.85 months SOC: 10.87 months MGMT Methylated MGMT Unm

  18. Slide 18: Second Recurrence Survival by Extent of Resection (post hoc analysis)

    Overall Survival – Second Recurrence Survival by Extent of Resection (post hoc analysis) Complete Resection Incomplete Resection HR=0.34 (95% CI: 0.06, 1.82) p-value=0.1897 Median OS: Toca: 27.43 months SOC: 13.01 months HR=0.45 (95% CI: 0.21, 0.98) p-value=0.0394 Median OS: Toca: 14.85 months SOC:

  19. Slide 19: Number of Cycles of Treatment

    Number of Cycles of Treatment Toca FC Metronomic TMZ TMZ Lomustine Bevacizumab n 197 18 31 66 26 Mean (SD) 3.4 (3.36) 4.7 (3.80) 4.4 (3.64) 2.3 (1.68) 6.2 (5.49) Median 2 3 3 2 4 Min, Max 1, 21 1, 11 1, 15 1, 7 1, 24 Lomustine as a single oral dose of 110 mg/m2 repeated every 6 weeks, or, Temozolomi

  20. Slide 20: Improvement of Survival is Dependent on Number of Toca FC Cycles

    Improvement of Survival is Dependent on Number of Toca FC Cycles Overall Survival – Toca 511 & Toca FC Arm (post hoc analysis) Intention-To-Treat – Toca 511 & Toca FC Arm 1 cycle 4+ cycles 3 cycles 2 cycles

  21. Slide 21: Trend between Treatment Duration and Survival (post hoc analysis)

    Overall Survival – ITT population Trend between Treatment Duration Analysis and Survival (post hoc analysis) HR=0.658 p-value=0.3230 Median OS: Toca: 31.97 months SOC: 24.74 months HR=0.497 p-value=0.2607 Median OS: Toca: NR (Not Reached) SOC: 24.74 months Treatment duration > 6 months Treatment dur

  22. Slide 22: Baseline Immune Balance Between Toca Arm and SOC Arm

    Baseline Immune Balance Between Toca Arm and SOC Arm Tumor PBMCs No significant differences were observed between the two arms at baseline Standard of Care Toca 511 & Toca FC Standard of Care Toca 511 & Toca FC

  23. Slide 23: Baseline Immune Differences Observed Between GBM and AA

    Baseline Immune Differences Observed Between GBM and AA Tumor# PBMCs * More robust immune profile for AA patients at baseline * AA GBM AA GBM #All significant Significant *

  24. Slide 24: Baseline Immune Differences Observed Between IDH1wt and IDH1mt

    Baseline Immune Differences Observed Between IDH1wt and IDH1mt PBMCs Greater potential to generate anti-tumor responses for patients with IDH1mt at baseline * * * * Tumor# IDH1wt IDH1mt IDH1wt IDH1mt #All significant Significant *

  25. Slide 25: Baseline Immune Differences Observed Between 1st & 2nd Recurrence

    Baseline Immune Differences Observed Between 1st & 2nd Recurrence PBMCs More Robust immune profile for patients with 2nd recurrence at baseline Tumor# #All significant * * * * * * * * * * 1st recurrence 2nd recurrence 1st recurrence 2nd recurrence Significant *

  26. Slide 26: Trial Remains on Track to Activate by end-2019

    Trial Remains on Track to Activate by end-2019 Chemoradiation à maintenance TMZ Chemoradiation à maintenance TMZ & Toca FC Surgery 1:1 Randomization Stratification Factors Age KPS (Optune® allowed) (No Optune® allowed) Toca 511 SOC NRG-BN006: Phase 2/3 Trial of Toca 511 & Toca FC in ndGBM Standard o

  27. Slide 27: Toca 6: Phase 1b Trial in Advanced Solid Tumors

    Phase 1b Trial in Advanced Solid Tumors Design Phase 1b, multicenter, open label (up to 30 patients) Patients with advanced solid tumors or lymphoma Study Results Favorable safety and tolerability (n=20) Confirmed vector deposition in “hot” and “cold” areas of metastatic tumors – Toca 511 penetrates

  28. Slide 28: Toca 8: Phase 1 Trial in Non-Muscle Invasive Bladder Cancer

    Toca 8: Phase 1 Trial of Intravesical Toca 511 Followed by Toca FC in Non-Muscle Invasive Bladder Cancer Objectives Primary - Safety and tolerability Secondary – Viral transduction and Phase 2 dose Exploratory – MOA and clinical “proof of concept” in a subset of patients unresponsive/intolerant to B

  29. Slide 29: Tocagen Pipeline

    Tocagen Pipeline Candidate Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Toca 511 & Toca FC Recurrent high grade glioma Newly diagnosed glioblastoma (in collaboration with NRG Oncology) Advanced solid tumors (CRC, pancreatic, sarcoma & lung) Recurrent high grade non-muscle invasive bladde

  30. Slide 30: 2019: Updated Financial Position and Near-Term Catalysts

    2019: Updated Financial Position and Near-Term Catalysts Toca 5 interim analysis expected in the second quarter of 2019 Advance Toca 511 & Toca FC in non-CNS tumor* Toca 5 topline results Report updated Toca 6 safety and immune activity data at Society for Immunotherapy of Cancer 2019 Present full T

  31. Slide 31: Thank you to all of the patients and families who have supported our work

    Thank you to all of the patients and families who have supported our work. Financial support also provided by:

Tocagen — Corporate Update (November 2019) on 6ix